Compugen (NASDAQ:CGEN) Posts Earnings Results, Misses Expectations By $0.20 EPS

Compugen (NASDAQ:CGEN) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20), Zacks reports. The company had revenue of $17.13 million during the quarter, compared to the consensus estimate of $17.67 million. Compugen had a return on equity of 2.61% and a net margin of 2.67%. During the same quarter in the prior year, the firm earned ($0.11) earnings per share.

Compugen Stock Up 0.6 %

Shares of Compugen stock traded up $0.01 during trading hours on Wednesday, reaching $1.61. 230,524 shares of the stock traded hands, compared to its average volume of 406,532. Compugen has a one year low of $0.55 and a one year high of $3.03. The firm has a market capitalization of $143.68 million, a price-to-earnings ratio of 80.50 and a beta of 2.64. The company has a 50 day moving average price of $1.77 and a 200 day moving average price of $1.88.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.